ABVC BioPharma (ABVC)
(Delayed Data from NSDQ)
$1.06 USD
-0.04 (-3.64%)
Updated May 10, 2024 04:00 PM ET
After-Market: $1.08 +0.02 (1.89%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for ABVC BioPharma, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 1 | 0 | 0 | 1 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 1 | 0 | 0 | 1 |
Selling & Adminstrative & Depr. & Amort Expenses | 8 | 16 | 12 | 9 | 4 |
Income After Depreciation & Amortization | -8 | -15 | -12 | -9 | -3 |
Non-Operating Income | 0 | 0 | 1 | -2 | 0 |
Interest Expense | 2 | 0 | 0 | 0 | 0 |
Pretax Income | -11 | -16 | -11 | -11 | -4 |
Income Taxes | 0 | 1 | 1 | 0 | 0 |
Minority Interest | 0 | 0 | 1 | -1 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -11 | -16 | -12 | -11 | -4 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -11 | -16 | -13 | -10 | -4 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -8 | -15 | -12 | -8 | -3 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -8 | -15 | -12 | -9 | -3 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 4.34 | 3.17 | 2.51 | NA | 1.75 |
Diluted EPS Before Non-Recurring Items | -2.43 | -5.20 | -5.10 | NA | -2.10 |
Diluted Net EPS (GAAP) | -2.43 | -5.20 | -5.10 | -5.00 | -2.10 |
Fiscal Year end for ABVC BioPharma, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.02 | 0.01 | 0.13 |
Cost Of Goods | NA | 0.14 | 0.03 | 0.07 | 0.06 |
Gross Profit | NA | -0.14 | -0.01 | -0.07 | 0.07 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 1.82 | 2.14 | 2.12 | 1.97 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -1.96 | -2.15 | -2.19 | -1.90 |
Non-Operating Income | NA | 0.28 | 0.00 | 0.08 | 0.07 |
Interest Expense | NA | 1.10 | 1.22 | 0.11 | 0.06 |
Pretax Income | NA | -3.15 | -3.37 | -2.23 | -1.90 |
Income Taxes | NA | 0.18 | 0.00 | 0.08 | 0.00 |
Minority Interest | NA | -0.22 | -0.05 | -0.05 | -0.07 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -3.33 | -3.37 | -2.32 | -1.90 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -3.11 | -3.32 | -2.26 | -1.82 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 4.34 | 4.06 | 3.31 | 3.31 |
Diluted EPS Before Non-Recurring Items | NA | -0.35 | -0.82 | -0.68 | -0.60 |
Diluted Net EPS (GAAP) | NA | -0.33 | -0.82 | -0.68 | -0.60 |